TGNA:FRA
Transgene SA
၀.၆၇ €
arrow_downward
-၀.၁၅%(-၀.၀၀၁၀၀) 1D
အောက် ၁၅, GMT+၂ ၂၂:၀၀:၀၀ · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for TGNA...
Open
၀.၆၇ €
High
၀.၆၇ €
Low
၀.၆၇ €
Mkt. cap
၁၉.၂၈ ကုဋေ
Avg. vol.
၀.၀၀
Volume
၀.၀၀
52-wk high
၁.၄၈ €
52-wk low
၀.၆၀ €
EPS
-၀.၁၇ €
No. of employees
၁၅၂
Open
၀.၆၇ €
High
၀.၆၇ €
Low
၀.၆၇ €
Mkt. cap
၁၉.၂၈ ကုဋေ
Avg. vol.
၀.၀၀
Volume
၀.၀၀
52-wk high
၁.၄၈ €
52-wk low
၀.၆၀ €
EPS
-၀.၁၇ €
No. of employees
၁၅၂
News stories
From web sources and news partners
Investor's Business Daily
·
ပြီးခဲ့သည့် ၄၉ မိနစ်
Anthropic Value Report Hits Tech Futures; Tesla Touts Roadster
Yahoo Finance
·
ပြီးခဲ့သည့် ၂၅ မိနစ်
The S&P 500 Went More Than 50 Trading Days Without a 1% Drop. That Streak Just Ended. What's Next?
The Spokesman-Review
·
ပြီးခဲ့သည့် ၉ မိနစ်
S&P 500 ends higher as traders shift from AI to healthcare
WSJ
·
ပြီးခဲ့သည့် ၅ နာရီ
Stocks Gain as Treasury Yields Give Back Some Recent Gains
Profile
Transgene S.A. is a French biotechnology company founded in 1979. It is based in Illkirch-Graffenstaden, near Strasbourg, Alsace. The company develops and manufactures immunotherapies for the treatment of cancer. Based on viral vectors, these therapies stimulate the immune defenses of patients to specifically target cancer cells.
Transgene has two technological platforms based on these respective approaches: individual therapeutic vaccines, shared antigens cancer vaccines oncolytic viruses.
Transgene's portfolio consists of four products currently in clinical development. Its lead product TG4050, a neoantigen individualized therapeutic cancer vaccine is currently being developed in a randomized Phase I/II trial in the adjuvant treatment of head and neck cancer.
The company is listed on the regulated market of Euronext in Paris. Wikipedia
About Transgene SA